R&D Trends

Innovate U.K., Medical Research Council award $47.1M

Monday, November 24, 2014 02:37 PM

Innovate U.K. and the Medical Research Council have awarded over $47.1 million in new funding through the Biomedical Catalyst, part of the U.K. government’s life sciences strategy.

More... »


OncoSec Medical, University of Washington ink research agreement

Friday, November 21, 2014 11:20 AM

OncoSec Medical, a San Diego-based company developing DNA-based intratumoral cancer immunotherapies, has entered a sponsored research agreement (SRA) with the University of Washington to evaluate the immunologic mechanisms of intratumoral DNA IL-12 electroporation.

More... »


Study: global spending on medicines to increase 30% by 2018, to $1.3 trillion

Thursday, November 20, 2014 01:38 PM

More specialty drug innovation, greater patient access to medicines and reduced impact from patent expiries will be the primary drivers of an increase in global medicine spending of up to 30% by 2018.

More... »

Genomics England calls on the U.K. research community

Wednesday, November 19, 2014 02:25 PM

Genomics England is inviting applications to join a new Clinical Interpretation Partnership from U.K. researchers, NHS Clinicians and those in training where they will work on the unique data resource from the 100,000 Genomes Project. The goal of the Genomics England Clinical Interpretation Partnership (GeCIP) is to bring together the best researchers in the U.K., alongside their key international collaborators, to ensure maximized potential to gaining new biological insights into rare inherited diseases, cancers and infectious disease.

More... »

Neuro-MAP, MRC Technology to jumpstart drug development for brain diseases

Wednesday, November 19, 2014 02:18 PM

Drugs for brain diseases such as dementia, motor neurone disease and Parkinson’s, which have stalled in development, could be revived thanks to up to $47.1 million in funding and resources from a global coalition of charities and funders. The Neurodegeneration Medicines Acceleration Program (Neuro-MAP), led by U.K. medical research charity MRC Technology, will help charities and funding bodies identify promising drug projects no longer in development and help scientists take them forward to the next stage.

More... »

Tufts CSDD: Developing, winning marketing approval for a new drug now cost $2.6 billion

Tuesday, November 18, 2014 02:22 PM

Developing and gaining marketing approval for a new prescription medicine, a process often lasting longer than a decade, is estimated to cost $2,558 million, according to a new study by the Tufts Center for the Study of Drug Development (CSDD).

More... »

Geron, Janssen collaborate to develop and commercialize imetelstat

Monday, November 17, 2014 02:36 PM

Geron, a Menlo Park, Calif.-based clinical stage biopharmaceutical company, has entered into an exclusive worldwide license and collaboration agreement with Janssen Biotech to develop and commercialize imetelstat, Geron`s telomerase inhibitor product candidate, for oncology, including hematologic malignancies and other human therapeutics uses.

More... »

Boehringer Ingelheim, WellPoint, HealthCore collaborate

Monday, November 17, 2014 02:34 PM

Boehringer Ingelheim Pharmaceuticals (BIPI); WellPoint, an Indiana-based, U.S. health benefit company; and HealthCore, a Wilmington, Del.-based wholly-owned subsidiary of WellPoint, are launching a research project to identify and address unmet medical needs.

More... »

Merck, Pfizer ink alliance on anti-PD-L1

Monday, November 17, 2014 02:28 PM

Merck has entered into a global agreement with Pfizer to co-develop and co-commercialize MSB0010718C, an investigational anti-PD-L1 antibody currently in development by Merck as a potential treatment for multiple tumor types to accelerate the two companies’ presence in immuno-oncology.

More... »

Bone Therapeutics, Kasios collaborate on optimization of spinal fusion procedures

Monday, November 17, 2014 02:27 PM

Bone Therapeutics, a Belgium regenerative therapy company addressing unmet medical needs releated to bone diseases and orthopaedics, and Kasios, a French synthetic bone substitute specialist, have announce a two-year collaboration to develop a novel product for spinal fusion procedures. The collaboration combines Bone Therapeutics' allogeneic osteoblastic cell therapy product ALLOB with Kasios's synthetic micro-granules bone substitute. The project is subsidized by the government of the Walloon Region.

More... »

CenterWatch
CWWeekly

January 26

2015 CRO outlook: M&As, IPOs, strategic partnerships and increased eClinical outsourcing expected to continue

IOM, industry stakeholders propose standards, guidelines for open sharing of clinical trial data

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January

All eyes on EMA’s adaptive licensing pilot
Sponsors could offer innovative drugs to patients 8 years sooner

Ice Bucket Challenge a boon for ALS research
Donations soar, but phenomenon difficult to replicate

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

December

Growing adoption of feasibility review committees
Early reports cite fewer amendments, improved cycle time

AMCs vying to better compete for industry trials
Working to conquer study start-up delays, IRB review process

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs